Background: The purpose of this study was to retrospectively analyse the clinical presentation of RSV, Influenza, and SARS-CoV-2 infections in children across three consecutive seasons (2022/2023; 2023/2024; and 2024/2025). Methods: Of the 321 hospitalised patients, 129 (36%) tested positive for RSV, 110 (38%) for Influenza, and 82 (26%) for SARS-CoV-2. Children were aged ≤ 17 years (median: 15 months). The data were statistically analysed using the χ2 test, multinomial multivariable logistic regression, OR (odds ratio), and 95% CI (confidence interval). Results: Significant independent predictors of RSV infection were auscultatory abnormalities (OR: 15.9 [1.49–169]) and hospital admission ≥ 4 days after symptom onset (OR: 32.5 [1.19–907]). Among RSV-positive patients, compared with those aged < 6 months, those aged 7–24 months were more likely to present with higher CRP levels (OR 1.06 [1.003–1.13]), reduced appetite (OR 6.7 [1.62–27.67]), and longer duration of fever (OR 7.22 [1.47–35.59]), while in children > 24 months, only a longer duration of fever remained significant (OR 16.82 [2.14–162.4]). In Influenza, reduced appetite was the only characteristic feature in the 7–24-month age group (OR 13.55 [1.79–102.81]). In COVID-19, children aged 7–24 months more frequently had higher CRP levels (OR 1.108 [1.001–1.226]) and chronic diseases (OR 7.59 [1.115–51.64]), whereas in those >24 months, only CRP was significant (OR 1.16 [1.047–1.31]). Conclusions: RSV was associated with severe respiratory manifestations and later hospital admission, whereas Influenza and SARS-CoV-2 were characterised by milder courses with predominant upper respiratory symptoms. Observed age- and virus-specific patterns highlight the importance of continued surveillance and comparative research on major respiratory viruses in children.
Pollen-food allergy syndrome (PFAS) is a common IgE-mediated allergic condition resulting from cross-reactions between pollen and plant food allergens, primarily those in the PR-10 subfamily. Mostly symptoms are limited to the mouth and throat causing oral allergy syndrome (OAS). Systemic reactions are extremely rare. We report an 11-year-old boy who experienced a unique anaphylactic reaction after consuming raw carrot juice. The patient exhibited symptoms within one minute, including abdominal pain, facial and eyelid swelling, dyspnea, a macular rash, choking sensation and drowsiness. Desloratadine alleviated these symptoms, and as his overall condition improved rapidly, there was no need for adrenaline administration. Carrot-specific IgE levels in the patient’s serum were as follows: Dau c: 40.63 kUA/L and Dau c1: 31.5 kUA/L. He had previously been diagnosed with seasonal allergic rhinoconjunctivitis. The high degree of similarity among allergen components within the PR-10 subfamily contributed to cross-reactivity between birch pollen and carrots. It is important to remember that PFAS can manifest systemically, with symptoms ranging from mild skin itching to potentially fatal consequences. This highlights the need for healthcare professionals to be extra cautious and aware of this possibility, especially since carrots are commonly found in a wide range of dishes and snacks.
Background: Measles has re-emerged in recent years as a public health concern in the context of insufficient vaccination coverage. Some children experience significant delays in receiving, or refuse to take, the measles, mumps and rubella (MMR) vaccination, often due to concerns related to hen’s egg allergy (HEA). Methods: In this study, we retrospectively assessed the safety of MMR vaccination (Priorix®, GlaxoSmithKline, Belgium) in patients with HEA hospitalised at our clinic. Detailed medical histories were collected, along with skin prick tests and measurements of specific IgE against milk and egg proteins or extracts. The study included 39 patients with a mean age of 19 months, of whom 15 had previously experienced an anaphylactic reaction after egg ingestion. Results: None of these patients experienced a systemic reaction to vaccination. One patient developed a generalised maculopapular rash, which resolved after a single dose of an antihistamine. Vaccination was postponed in 63% of patients, with the longest delay extending to 113 months. Conclusions: Severe adverse reactions following MMR vaccination in patients with HEA are generally rare and are outweighed by the risks associated with natural infection and its complications. Effective communication of vaccine safety data and strengthening public trust in healthcare professionals are crucial.
Alergiczny nieżyt nosa (ANN) jest jedną z najczęściej występujących chorób przewlekłych na świecie. Postępowanie w ANN opiera się na strategii obejmującej: unikanie alergenów, farmakoterapię oraz immunoterapię alergenową. Donosowe glikokortykosteroidy (nGKS) oraz doustne lub donosowe leki przeciwhistaminowe (LH1) są kluczowymi elementami terapii. Jednakże, pomimo ich skuteczności, wielu pacjentów nadal doświadcza niedostatecznej kontroli objawów lub oczekuje szybszego ustąpienia dolegliwości. Kluczową zaletą połączenia furoinianu mometazonu (nGKS) i chlorowodorku olopatadyny (donosowy lek przeciwhistaminowy) jest ich komplementarne i synergistyczne działanie na złożoną patofizjologię ANN. Liczne badania kliniczne potwierdzają większą skuteczność donosowego połączenia olopatadyny i mometazonu (Olo-Mom) nad monoterapią oraz placebo w leczeniu alergicznego nieżytu nosa – zarówno sezonowego (SAR), jak i całorocznego (PAR). Połączenie LH1 + nGKS może być również związane z poprawą jakości życia i objawów ocznych u dzieci z SAR. Kluczowe zalety i korzyści połączenia Olo-Mom to: synergistyczne działanie, wyższa skuteczność kliniczna, szybkość działania, wysoka satysfakcja pacjenta i lepsza adherencja oraz korzystny profil bezpieczeństwa. Podsumowując, dowody naukowe wyraźnie wskazują, że połączenie furoinianu mometazonu i chlorowodorku olopatadyny oferuje kompleksową i szybką ulgę w objawach alergicznego nieżytu nosa, przewyższając skutecznością monoterapię i placebo, co czyni je cennym narzędziem w terapii ANN.
Approximately 1–2% of infants have cow’s milk protein allergy (CMPA). From a clinical perspective, diagnosing CMPA using the oral food challenge (OFC) is high risk, necessitating safer alternatives. One possible alternative is component-resolved diagnostics (CRD). This narrative review examines specific IgE (sIgE) thresholds for cow’s milk protein in predicting outcomes of OFCs in European children. Eligible studies focusing on CRD in European pediatric populations were identified through PubMed and Scopus databases. Our findings highlight the crucial role of Bos d 8 (casein) in the diagnostic process. Among the analyzed milk components, Bos d 8 appeared to be a promising marker for predicting positive OFC outcomes in several cohorts. However, due to significant population heterogeneity, conflicting findings exist, with some studies indicating that no single molecular component is consistently superior to whole cow’s milk specific IgE. While other molecules, such as Bos d 6 and lactoferrin, showed limited diagnostic utility, specific IgE to Bos d 8 demonstrated the highest clinical value. Although the double-blind, placebo-controlled food challenge (DBPCFC) remains the gold standard for CMPA diagnosis, the use of Bos d 8 in CRD is a key step toward risk stratification and may help reduce the need for high-risk OFCs in selected patients.